Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab rezetecan + Apatinib in Advanced Gastric/GEJ and Colorectal Cancer
NCT06666166Phase 2Not yet recruiting
- Sponsor
- Yunpeng Liu
- Start
- Dec 2024
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab rezetecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and colorectal cancer (CRC) (2 arms), sponsored by Yunpeng Liu. Primary endpoint: Objective Response Rate at 6 months. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06666166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06666166.